Tokyo, June 16, 2006 (JCN) - Dainippon Sumitomo Pharma will release AmBisome 50mg for intravenous drip infusion, an antifungal agent for treating deep-seated mycosis infection, on June 20. AmBiosome, which the company has licensed from US company Gilead Sciences, is a liposomal formulation of amphotericin B. It retains the efficacy of amphotericin B while reducing the damage to kidneys.
